Rationale for (−)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes

This publication has 34 references indexed in Scilit:

• Chronic treatment of (-)deprenyl prolongs the life span of male fischer 344 rats. Further evidence
  Life Sciences, 1993
• (−)Deprenyl increases activities of superoxide dismutase and catalase in striatum but not in hippocampus: The sex and age-related differences in the optimal dose in the rat
  Experimental Neurology, 1992
• Parkinson's disease: management
  The Lancet, 1991
• (−) deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats
  Life Sciences, 1991
• Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B
  European Journal of Pharmacology, 1990
• Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm study
  Journal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1985
• Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys
  European Journal of Pharmacology, 1984
• Deprenyl (selegiline): the history of its development and pharmacological action
  Acta Neurologica Scandinavica, 1983
• The possible mechanisms of action of (-)deprenyl in Parkinson's disease
  Journal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1978
• Age-related Changes in the Nigrostriatum: A Behavioral and Biochemical Analysis
  Journal of Gerontology, 1978